Biseptol 480 mg

Quick links

Choose a section

Quick links to important sections

Advertisements

Biseptol 480 mg

Selected form

Advertisements
Advertisements

Overview of Biseptol 480 mg

Quick Facts

Property Description
Active Ingredients Sulfamethoxazole (SMX) and Trimethoprim (TMP)
Form Oral Tablet (most common strength)
Pharmacological Class Broad-Spectrum Antibacterial Agent
Primary Classification Fixed-Dose Combination (FDC)
Origin Synthetic Compound

What Type of Medication is Biseptol 480 mg?

Biseptol 480 mg is a synthetic, prescription-only, fixed-dose combination medication, globally recognized by the generic name Co-trimoxazole or TMP-SMX. It is definitively classified as a broad-spectrum antibacterial agent, designed to control the proliferation of susceptible microscopic organisms. Its function as a chemically synthesized chemotherapeutic product, rather than a naturally derived antibiotic, is clinically recognized for providing effective microbial control in targeted scenarios. This agent is routinely prescribed when a dependable, multi-spectrum approach is necessary to halt bacterial activity.

The Active Composition of Biseptol 480 mg

The clinical activity of the drug relies on its two active ingredients: Sulfamethoxazole (SMX), a component from the sulfonamide class, and Trimethoprim (TMP), a derivative of the diaminopyrimidine group. The oral tablet form is typically manufactured with the two components in a fixed ratio of 5 parts SMX to 1 part TMP. This specific 480 mg strength refers to the total combined weight of the active ingredients in the oral tablet. The product is typically presented as a plain, scored tablet designed for ease of oral administration in adult patient groups.

General Purpose and Benefit of this Combination

The general therapeutic purpose of Co-trimoxazole is to control and halt the growth of susceptible bacteria through a synergistic bacteriostatic effect. This dual-action mechanism involves interrupting two separate, vital steps in the bacterial production of genetic and structural materials. This unique sequential blockade strategy allows the body to effectively manage and clear the non-replicating bacterial population, which is the foundational benefit underlying its use for common bacterial challenges.

Regulatory References

  1. Co-trimoxazole Drug Information
  2. Co-trimoxazole on WHO Essential Medicines List
Advertisements

What side effects are possible with Biseptol 480 mg?

Possible Side Effects and Safety Information

This section outlines the documented side effects and safety profile of Biseptol 480 mg (Co-Trimoxazole) as classified in official regulatory documents. This information is descriptive and not intended as advice or instruction for use.


Documented Adverse Reactions

Side effects are categorized by frequency and the body system affected (System-Organ Class or SOC):

Frequency Category Examples of Documented Reactions
Very Common Hyperkalemia (high potassium levels)
Common Nausea, Diarrhea, Headache, Rash, Fungal Overgrowth (e.g., Candida)
Uncommon Vomiting
Very Rare Severe skin reactions (Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis), blood disorders (Agranulocytosis, Aplastic Anaemia), severe liver or kidney failure, Aseptic Meningitis.

Serious Adverse Reactions

Rare but clinically significant reactions documented in regulatory sources include life-threatening cutaneous events (SJS, TEN), severe blood dyscrasias (e.g., Agranulocytosis, Thrombocytopenia), and severe organ damage such as fulminant hepatic necrosis. The highest risk for severe skin reactions is generally reported within the first weeks of treatment.


Safety Restrictions and Monitoring

Biseptol is contraindicated in several specific situations due to elevated risk, including:

  • Infants under two months of age (risk of Kernicterus).
  • Patients with documented severe hepatic damage or severe renal insufficiency where function cannot be monitored.
  • Individuals with known Porphyria or megaloblastic anemia due to folate deficiency.

Patients on prolonged therapy may require regular blood examinations for safety monitoring. Treatment must be discontinued immediately if a skin rash appears.

Advertisements

Overdose and Emergency Response

In the event of a suspected or confirmed overdose of Biseptol (sulfamethoxazole and trimethoprim), it is critical to seek emergency medical attention immediately. Overdose is considered a serious event that can present in two primary ways: acutely or through chronic, high-dose exposure.

Acute and Chronic Overdose Presentation

Acute Overdose symptoms typically affect the gastrointestinal and central nervous systems, including: loss of appetite (anorexia), severe nausea, vomiting, dizziness, headache, drowsiness, and confusion. More severe acute manifestations can include convulsions (seizures), fever (pyrexia), and signs of organ involvement such as hematuria (blood in the urine) or jaundice (yellowing of the skin/eyes).

Chronic Overdose, resulting from prolonged exposure to high doses, is characterized by a major risk of bone marrow depression. This can manifest as severe blood disorders (blood dyscrasias) including megaloblastic anemia, leukopenia (low white blood cell count), and thrombocytopenia (low platelet count).

When to Seek Immediate Medical Help

Call for emergency medical assistance if any symptoms of overdose are present, particularly if the person shows:

  • Confusion or loss of consciousness.
  • Convulsions (seizures).
  • Trouble breathing.
  • Yellowing of the skin or eyes (jaundice).
  • Blood in the urine (hematuria) or signs of systemic toxicity.

Overdose management is symptomatic and supportive, and the need for urgent care is based on the potential for severe, life-threatening effects on the blood and organs.

Advertisements

Therapeutic Uses of Biseptol 480 mg

What Biseptol 480 mg Treats: Main Uses and Benefits

The medication is commonly used to help manage a wide range of susceptible conditions where symptoms are related to bacterial processes, providing supportive symptomatic relief across key domains where infections cause acute distress and functional interference.

Biseptol is relevant across conditions presenting with acute episodes, including infections of the urinary tract (like cystitis and pyelonephritis), respiratory system (such as acute exacerbations of chronic bronchitis and otitis media), and specific bacterial causes of acute gastrointestinal distress (like shigellosis and Traveler's Diarrhea). It is also considered relevant for long-term supportive management against severe opportunistic illnesses, such as Pneumocystis jirovecii pneumonitis (PJP), in immunocompromised patients.

“The medication helps address symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases.” It provides support that helps ease the overall symptom burden, whether addressing symptoms related to physical discomfort during urination or managing symptoms related to systemic imbalance caused by respiratory or gastrointestinal infections.


Quick Fact: Supportive Management for Acute Discomfort

  • Target Symptoms: Pain or burning during urination (dysuria), fever, cough, purulent sputum, and acute, frequent loose stools.
  • Context of Use: Applied in clinical settings that involve acute or unstable symptom patterns, and for long-term supportive management.
  • Patient Benefit: Contributes to improved comfort and assists with maintaining functional stability during episodes of heightened discomfort.

Regulatory References

  1. SULFAMETHOXAZOLE AND TRIMETHOPRIM tablet - DailyMed - NIH
Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Biseptol 480 mg (Co-trimoxazole)

This medicine is restricted to certain patient populations based on official regulatory labeling (Summary of Product Characteristics and Prescribing Information).

Contraindicated Populations (Must NOT use):

  • Individuals with known hypersensitivity or allergy to trimethoprim, sulfamethoxazole, or any other sulphonamide derivatives.
  • Patients with severe hepatic damage or severe renal insufficiency (kidney failure, especially if monitoring is inadequate).
  • Patients diagnosed with megaloblastic anaemia due to folate deficiency, acute porphyria, or a history of drug-induced immune thrombocytopenia.
  • Newborn infants or premature babies less than 2 months of age.
  • Pregnant women and nursing mothers of premature or G6PD-deficient infants.

Populations Requiring Conditional or Restricted Use:

  • Elderly patients require particular care and often increased monitoring due to increased sensitivity to adverse effects.
  • Patients with mild to moderate renal impairment require a reduced dosage as defined in the prescribing information.
  • Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or known folate deficiency should use the medicine with caution and under close supervision.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents classify interactions with Biseptol 480 mg (Sulfamethoxazole-Trimethoprim) based on their impact on co-administered substances. These documented interactions establish specific constraints on co-administration.

Interaction Classifications and Restrictions

The co-administration of the antiarrhythmic medicine Dofetilide is absolutely contraindicated due to the risk of serious ventricular arrhythmias. This restriction is based on an official finding that the drug combination significantly increases Dofetilide plasma concentrations.

Mechanism Basis Interacting Substances Official Outcome Statement
Metabolic Inhibition Warfarin, Phenytoin Increases exposure; prolongs half-life; inhibits metabolism.
Pharmacodynamic Thiazide Diuretics, ACE Inhibitors Increased risk of thrombocytopenia or hyperkalaemia.
Clearance Reduction Digoxin, Methotrexate, Procainamide Increases plasma levels; reduces renal secretion.

Co-trimoxazole also reduces the plasma half-life of its own components when concurrently administered with Rifampicin. Interaction relevance is heightened in elderly patients, who face an increased risk of thrombocytopenia with thiazide diuretics and higher Digoxin blood levels. Furthermore, Trimethoprim formally causes interference with creatinine estimation in lab assays.

Advertisements

Mechanism of Action

Biseptol 480 mg, a fixed-dose combination of Sulfamethoxazole (SMX) and Trimethoprim (TMP), acts through a sequential dual blockade on the essential metabolic process of susceptible microorganisms.

Double Blockade of Microbial Folate Biosynthesis

This combination targets the folate synthesis pathway, which is crucial for microbial replication. SMX is a competitive inhibitor of the enzyme Dihydropteroate Synthase (DHPS). TMP is a reversible inhibitor of Dihydrofolate Reductase (DHFR). This combined inhibition prevents the synthesis of purine and pyrimidine precursors required for microbial DNA and protein production, leading to the physiological consequence of suppressed microbial proliferation.

Selective Toxicity and Secondary Modulation

This mechanism exploits the metabolic difference between the microbe and the host, as human cells acquire pre-formed folate from the diet, thus bypassing the blocked pathway, which dictates the drug’s selective toxicity. Additionally, TMP can influence renal ion transport in the host kidney, modulating systemic potassium levels independently of its primary anti-folate action.

Advertisements

Dosage and Administration Information

The administration of Biseptol 480 mg, known generically as Co-trimoxazole, must strictly follow the instructions for dosage, frequency, route, and duration.

Official Administration Routes and Form

Biseptol 480 mg is an oral formulation, containing 80 mg Trimethoprim (TMP) and 400 mg Sulfamethoxazole (SMX). The drug is officially administered via the oral route (tablet or suspension), or as an Intravenous (IV) Infusion for moderate to severe conditions.

Standard Dosing and Frequency

The standard adult dose for most acute conditions is the equivalent of 160 mg TMP / 800 mg SMX, taken twice daily (every 12 hours). For certain high-dose regimens, such as the treatment of Pneumocystis jirovecii pneumonitis (PJP), the dose is significantly higher, administered in three or four divided doses per day.

Regimen Type Dosage Equivalent (TMP/SMX) Frequency
Standard Acute Dose 160 mg / 800 mg Every 12 hours
PJP Treatment 15 to 20 mg/ kg/ day of TMP component Divided every 6 to 8 hours

Administration Conditions and Duration

Oral tablets should be taken with some food or drink to potentially minimize gastrointestinal disturbances. Patients are advised to maintain adequate fluid intake during treatment. The duration of therapy for acute infections is a minimum of five consecutive days and continues until the patient has been symptom-free for two full days.

Dose Adjustments

Modification of the standard dosage is a required procedure for patients with reduced renal function. For individuals with a Creatinine Clearance (CrCl) of 15 to 30 mL/ min, the standard procedure is to administer half the usual dose or dose every 24 hours. Use is generally not recommended when CrCl is below 15 mL/ min.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Biseptol 480 mg

This section outlines the structure of available research for Biseptol 480 mg, reporting what types of studies have been conducted and the populations they involved, without stating specific clinical results or efficacy claims.


Evidence for Use in Urinary Tract Infections (UTI)

Research exploring Biseptol 480 mg for conditions characterized by episodic manifestations, such as urinary tract infections, often involves short-term clinical trials where patients were observed over a defined time interval. The research so far describes patterns where measured outcomes related to systemic or functional imbalance were observed in the populations during the study period. What remains unclear is how consistent these patterns are across all patient groups, and whether the observed changes continue after the short study periods end.


Evidence for Use in Acute Exacerbations of Chronic Bronchitis

Studies explored Biseptol 480 mg in individuals experiencing acute or disruptive episodes, such as sudden worsenings of chronic bronchitis. Findings describe patterns observed in the studies regarding phases of heightened symptom activity, contributing to understanding the progression of these episodic changes. A key limitation is that follow-up durations were typically limited, meaning long-term effects are not fully established.


Evidence for Use in Pneumocystis jirovecii Pneumonia (PJP)

Biseptol 480 mg was also evaluated in research contexts involving physiological strain, specifically in patients at risk for or diagnosed with Pneumocystis jirovecii pneumonia (PJP), often in immunocompromised settings. Reported outcomes were short-term and often based on modest sample sizes. Uncertainty remains, as certainty is low regarding long-term outcomes and the evolution of measured outcomes in these populations.


Long-Term Studies and Follow-up

Research focusing on extended outcomes for Biseptol 480 mg is generally limited. While studies examining short-term outcomes are available, long-term effects are not fully established across the indications. Long-term outcomes are not well characterized, and research provides context but not individual predictions for sustained health over time.


Evidence in Special Populations

Existing studies provide limited information on how Biseptol 480 mg was evaluated in all possible patient groups. Few data are available for pediatric patients younger than 2 years. Evidence quality differs across studies when comparing older adults and younger patient groups, and subgroup findings are often uncertain. Results generally apply only to the populations studied in the research.

Key Studies & References

  1. Trimethoprim Sulfamethoxazole - StatPearls (Indications and Overview)
  2. Pneumocystis pneumonia (PCP) - Therapeutic Guidelines (Relevant for PJP populations and prophylaxis)
  3. Trimethoprim/sulfamethoxazole (Co-trimoxazole) for acute urinary tract infections: A clinical overview
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Biseptol 480 mg (FAQ)

Q: How long does it take for Biseptol 480 mg to start working?

Clinical trial data suggests some effect may be noticeable within one to two weeks. However, patients should not expect to feel the full benefit immediately. The full therapeutic benefit may take four weeks or longer to develop, based on clinical studies.

If there is no change after approximately one month, it is important to follow up with your prescribing healthcare provider.

Q: Can I stop taking Biseptol 480 mg once I feel better?

Stopping treatment suddenly is not recommended and should only be done under the supervision of a healthcare provider. Abrupt discontinuation may result in discontinuation symptoms and could lead to a return of the original condition, based on product labeling.

Patients should always consult with their healthcare provider before making any changes to their regimen. The healthcare provider will determine the appropriate plan for gradually reducing the dose.

Q: Is Biseptol 480 mg safer than older medications for this condition?

The clinical safety profile of the drug, as described in product labeling, may differ from older medications for the same condition. As with any medication, individual patient tolerance varies.

Effectiveness is generally evaluated on an individual basis under the guidance of a healthcare provider. Side effect data and comparative information are available in the official prescribing information.

Advertisements

How should Biseptol 480 mg be stored and disposed of?

How to Store and Dispose of Biseptol 480 mg?

The storage and disposal of Biseptol 480 mg (sulfamethoxazole-trimethoprim) must adhere strictly to official regulatory guidelines to maintain drug quality and ensure safety.

Official Storage and Handling Requirements

Requirement Specific Instruction
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not refrigerate the injection solution.
Light & Container Keep the container tightly closed. Protect the oral suspension from light.
Child Safety Keep this medicine and all drugs locked up and out of the reach of children.
Stability Do not use the drug if it is expired or if the original container seal is broken.

Official Disposal Rules

Dispose of unused or expired medicine through an approved waste disposal process in accordance with local, national, or international regulations. The formulation should not be released to the environment or allowed to enter sewers or surface water, as it is classified as potentially toxic to aquatic life.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Biseptol 480 mg found in:

A-Z Index: